PD-1 abrogates the prolonged persistence of CD8+ CAR-T cells with 4-1BB co-stimulation

Feng Li; Zhen Zhang; Yujing Xuan; Daiqun Zhang; Jinyan Liu; Aitian Li; Shumin Wang; Ting Li; Xiaojuan Shi; Yi Zhang

doi:10.1038/s41392-020-00277-6

PD-1 abrogates the prolonged persistence of CD8⁺ CAR-T cells with 4-1BB co-stimulation

Signal Transduct Target Ther. 2020 Aug 25;5(1):164. doi: 10.1038/s41392-020-00277-6.

Authors

Feng Li^#^{1

2

3

4}, Zhen Zhang^#^{5

6

7

8}, Yujing Xuan^#^{5

6

7}, Daiqun Zhang^{5

6

7

9}, Jinyan Liu^{5

6

7}, Aitian Li^{5

6

7}, Shumin Wang^{5

6

7}, Ting Li^{5

6

7}, Xiaojuan Shi^{5

6

7}, Yi Zhang^{10

11

12

13

14}

Affiliations

¹ Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. lifeng01@msn.com.
² Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. lifeng01@msn.com.
³ State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou, Henan, China. lifeng01@msn.com.
⁴ Henan Key Laboratory for Tumor Immunology and Biotherapy, Zhengzhou, Henan, China. lifeng01@msn.com.
⁵ Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
⁶ Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
⁷ State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou, Henan, China.
⁸ Henan Key Laboratory for Tumor Immunology and Biotherapy, Zhengzhou, Henan, China.
⁹ School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China.
¹⁰ Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. yizhang@zzu.edu.cn.
¹¹ Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. yizhang@zzu.edu.cn.
¹² State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou, Henan, China. yizhang@zzu.edu.cn.
¹³ Henan Key Laboratory for Tumor Immunology and Biotherapy, Zhengzhou, Henan, China. yizhang@zzu.edu.cn.
¹⁴ School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China. yizhang@zzu.edu.cn.

^# Contributed equally.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Animals
CD8-Positive T-Lymphocytes / drug effects
Cell Line, Tumor
Humans
Immunotherapy, Adoptive*
Mice
Programmed Cell Death 1 Receptor / genetics*
Receptors, Chimeric Antigen / genetics*
Tumor Necrosis Factor Receptor Superfamily, Member 9 / genetics*
Xenograft Model Antitumor Assays

Substances

PDCD1 protein, human
Programmed Cell Death 1 Receptor
Receptors, Chimeric Antigen
TNFRSF9 protein, human
Tumor Necrosis Factor Receptor Superfamily, Member 9